CD133 and Ki-67 expression is associated with gastrointestinal stromal tumor prognosis

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1289-1294

  Lu, Canrong ^a   Liu, Licheng ^a   Wu, Xin ^a   Xu, Wentong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CD117; CD133; Gastrointestinal stromal tumors; Ki 67; Prognosis

Indexed keywords

CD133 ANTIGEN; IMATINIB; KI 67 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; SURVIVAL RATE;

EID: 84884491158     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1564     Document Type: Article

References (31)

1. Gupta P, Tewari M and Shukla HS: Gastrointestinal stromal tumors. Surg Oncol 17: 129-138, 2008.
2. Katz SC and De Matteo RP: Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol 97: 350-359, 2008.
3. Delahaye NF, Rusakiewicz S, Martins I, et al: Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 17: 700-707, 2011.
4. Kikuta K, Kubota D, Saito T, et al: Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients with gastrointestinal stromal tumor. J Proteomics 75: 1089-1098, 2012.
5. González-Cámpora R, Delgado MD, Amate AH, et al: Old and new immunohistochemical markers for the diagnosis of gastrointestinal stromal tumors. Anal Quant Cytol Histol 33: 1-11, 2011.
6. Zong L, Chen P and Xu Y: Correlation between P53 expression and malignant risk of gastrointestinal stromal tumors: evidence from 9 studies. Eur J Surg Oncol 38: 189-195, 2012.
7. de Oliveira AT, Pinheiro C, Longatto-Filho A, et al: Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J Bioenerg Biomembr 44: 171-178, 2012.
8. Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012, 1997.
9. Shmelkov SV, St Clair R and Lyden D and Rafii S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol 37: 715-719, 2005.
10. Chen YC, Hsu HS, Chen YW, et al: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE 3: e2637, 2008.
11. Matsumoto K, Arao T, Tanaka K, et al: mTOR signal and hypoxiainducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 69: 7160-7164, 2009.
12. Qin K, Jiang X, Zou Y, et al: Study on the proliferation and drug resistance of human brain tumor stem like cells. Cell Mol Neurobiol 30: 955-960, 2010.
13. Moriyama T, Ohuchida K, Mizumoto K, et al: Enhanced cell migration and invasion of CD133+ pancreatic cancer cells cocultured with pancreatic stromal cells. Cancer 116: 3357-3368, 2010.
14. Ding W, You H, Dang H, et al: Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology52: 945-953, 2010.
15. Arne G, Kristiansson E, Nerman O, et al: Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer 129: 1149-1161, 2011.
16. Wong NA, Young R, Malcomson RD, et al: Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 43: 118-126, 2003.
17. Nakamura N, Yamamoto H, Yao T, et al: Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol36: 828-837, 2005.
18. Miettinen M and Lasota J: KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol13: 205-220, 2005.
19. Elias J (ed): Immunhistopathology: A Practical Approach to Diagnosis. ASCP Press, Chicago, IL, 1990.
20. Taylor CR: Immunoperoxidase techniques: practical and theoretical aspects. Arch Pathol Lab Med 102: 113-121, 1978.
21. Joensuu H: Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39: 1411-1419, 2008.
22. Dematteo RP: Personalized therapy: prognostic factors in gastrointestinal stromal tumor (GIST). J Gastrointest Surg 16: 1645-1647, 2012.
23. McCarter MD, Antonescu CR, Ballman KV, etal; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant Gist Study Team: Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg215: 53-59, 2012.
24. Attili SV, Ananda B, Mandapal T, et al: Factors influencing progression-free survival in gastrointestinal stromal tumors with special reference to pathologic features, cytogenetics, and radiologic response. Gastrointest Cancer Res 4: 173-177, 2011.
25. Weigmann A, Corbeil D, Hellwig A and Huttner WB: Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of nonepithelial cells. Proc Natl Acad Sci USA94: 12425-12430, 1997.
26. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
27. Chew MF, Teoh KH and Cheah PL: CD133 marks for colorectal adenocarcinoma. Malays J Pathol 34: 25-28, 2012.
28. Reggiani Bonetti L, Migaldi M, Caredda E, et al: Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. Scand J Gastroenterol47: 1211-1217, 2012.
29. Hutchins JR, Toyoda Y, Hegemann B, et al: Systematic analysis of human protein complexes identifies chromosome segregation proteins. Science 328: 593-599, 2010.
30. Artigiani Neto R, Logullo AF, Stávale JN and Lourenço LG: Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST). Acta Cir Bras 27: 315-321, 2012.
31. Lamba G, Ambrale S, Lee B, et al: Recent advances and novel agents for gastrointestinal stromal tumor (GIST). J Hematol Oncol 5: 21, 2012.